Hematologic response and survival in IgM-related amyloidosis. (A) Changes in monoclonal immunoglobulin levels (MIg) and serum free chain levels (dFLC) during ibrutinib therapy in individual patients. (B) Overall survival (OS) and event-free survival (EFS) in patients with IgM-associated AL treated with ibrutinib. Event defined as death, relapse/progression, or next therapy. BR, best response; Cum, cumulative.